These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35641024)

  • 1. Tolvaptan induces body fluid loss and subsequent water conservation in normal rats.
    Kidoguchi S; Kitada K; Fujisawa Y; Nakano D; Yokoo T; Titze J; Nishiyama A
    J Pharmacol Sci; 2022 Jul; 149(3):115-123. PubMed ID: 35641024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.
    Masuda T; Murakami T; Igarashi Y; Okabe K; Kobayashi T; Takeda SI; Saito T; Sekiguchi C; Miyazawa Y; Akimoto T; Saito O; Muto S; Nagata D
    Intern Med; 2016; 55(19):2759-2764. PubMed ID: 27725533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan Reduces Extracellular Fluid per Amount of Body Fluid Reduction Less Markedly than Conventional Diuretics.
    Iwatani H; Yamato M; Bessho S; Mori Y; Notsu S; Asahina Y; Koizumi S; Kimura Y; Shimomura A
    Intern Med; 2022 Sep; 61(17):2561-2565. PubMed ID: 35110480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
    Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
    J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
    Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.
    Miyazaki T; Yamamura Y; Onogawa T; Nakamura S; Kinoshita S; Nakayama S; Fujiki H; Mori T
    Endocrinology; 2005 Jul; 146(7):3037-43. PubMed ID: 15831573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB
    BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan as a tool in renal physiology.
    Miranda CA; Lee JW; Chou CL; Knepper MA
    Am J Physiol Renal Physiol; 2014 Feb; 306(3):F359-66. PubMed ID: 24305472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Ito H; Mizumoto T; Tempaku H; Fujinaga K; Sawada Y; Shimpo H
    J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1471-1478. PubMed ID: 27591907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.
    Mori T; Oba I; Koizumi K; Kodama M; Shimanuki M; Tanno M; Chida M; Saito M; Kiyomoto H; Miyazaki M; Ogawa S; Sato H; Ito S
    Adv Perit Dial; 2013; 29():33-7. PubMed ID: 24344488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure.
    Ishikawa M; Kobayashi N; Sugiyama F; Onoda S; Ishimitsu T
    Int Heart J; 2013; 54(2):98-106. PubMed ID: 23676370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan.
    Fujiki H; Matsunaga M; Furukawa M; Yamashita T; Nakamura S; Miyazaki T; Mizuguchi H; Menjo Y; Matsuda T; Yamada Y
    J Pharmacol Sci; 2022 Nov; 150(3):163-172. PubMed ID: 36184121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models.
    El-Shabrawy M; Mishriki A; Attia H; Emad Aboulhoda B; Emam M; Wanas H
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00659. PubMed ID: 32996719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.
    Nagayama I; Masuda T; Nakagawa S; Murakami T; Ohara K; Matsuoka R; Kobayashi T; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Intern Med; 2019 Jun; 58(11):1587-1591. PubMed ID: 30713322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advent of New perioperative care for fluid management after cardiovascular surgery: A review of current evidence.
    Nishi H
    J Cardiol; 2020 Jun; 75(6):606-613. PubMed ID: 31980355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.
    Nakanishi H; Kurosaki M; Hosokawa T; Takahashi Y; Itakura J; Suzuki S; Yasui Y; Tamaki N; Nakakuki N; Takada H; Higuchi M; Komiyama Y; Yoshida T; Takaura K; Hayashi T; Kuwabara K; Sasaki S; Izumi N
    J Gastroenterol; 2016 Jun; 51(6):620-7. PubMed ID: 26610908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.